Dihexa vs GHK-Cu
Both compounds occupy the cognitive-plasticity research space but from very different angles. Dihexa is a direct synaptogenic agent — its flagship finding is picomolar-concentration dendritic spine formation on hippocampal pyramidal neurons via HGF/c-Met signalling. GHK-Cu is an endogenous copper-binding tripeptide with distinctive broad gene-expression modulation and multi-pathway effects on cellular repair, antioxidant defence, and inflammatory modulation.
At a glance
| Dihexa | GHK-Cu | |
|---|---|---|
| Structural class | Angiotensin IV-derived hexapeptide (engineered) | Endogenous copper-binding tripeptide |
| Primary route | Oral (propylene glycol vehicle) | Subcutaneous, topical, or oral (with delivery vehicle) |
| Signature mechanism | HGF / c-Met axis engagement → synaptogenesis | Broad gene-expression modulation (~4000 genes) |
| Cognitive-relevance angle | Dendritic spine formation, cognitive-plasticity direct | Anti-inflammatory, antioxidant, cellular-stress-resistance — indirect cognitive-decline mechanisms |
| Clinical evidence base | Preclinical only, no human cognitive-endpoint trials | Preclinical broad, some dermatological clinical use, no human cognitive-endpoint trials |
| Evidence tier | C | C |
| Endogenous presence | No — engineered research compound | Yes — endogenous copper-peptide with age-declining plasma levels |
| UK status | No emc entry found (checked 17 October 2026) | No emc entry found (checked 17 October 2026) |
Focused mechanism vs broad footprint
Two research-tool positioning angles for cognitive-decline research
Dihexa's positioning is that of a focused-mechanism research tool. It engages a specific signalling axis (HGF/c-Met) to produce a specific cellular effect (dendritic spine formation) at a specific concentration range (picomolar). This focused positioning makes Dihexa well-suited to research questions where the mechanism of interest is synaptogenesis specifically — cognitive-ageing research, cognitive-plasticity mechanism research, and Alzheimer's-model synaptic-preservation research.
GHK-Cu's positioning is that of a broad-footprint research tool. Its distinctive gene-expression modulation across roughly 4000 transcripts spans DNA-repair, inflammatory-modulation, antioxidant-defence, cellular-stress-resistance, and tissue-regeneration pathways. This broad positioning makes GHK-Cu well-suited to research questions where the mechanism of interest is broad cellular-repair or pleiotropic anti-ageing intervention — the compound's dermatological research applications and wound-healing applications draw on this same broad mechanism footprint.
For cognitive-decline research the two positioning angles are complementary. Dihexa addresses the synaptic-plasticity contribution to cognitive decline; GHK-Cu addresses the broader neuroinflammation and cellular-stress-resistance contributions. Research designs that need to probe both cognitive-decline mechanism contributions could plausibly draw on both compounds.
Endogenous versus engineered
Sourcing, safety framework, and research-tool positioning
GHK-Cu is endogenous — present in human plasma at concentrations that decline with age. This endogenous status provides a partial safety floor at physiological concentrations and a rationale for the compound's use as a copper-peptide-supplementation intervention against age-related copper-peptide decline. Dihexa is engineered — the Washington State University group specifically designed the hexapeptide chemistry to produce oral bioavailability and blood-brain barrier penetration from the angiotensin IV starting scaffold. This engineered nature means Dihexa has no endogenous-safety baseline; the pharmacology must be evaluated purely on experimental data.
Research-tool positioning implications: GHK-Cu's endogenous status and dermatological/cosmeceutical commercial availability provide sourcing options that Dihexa lacks. Dihexa's engineered status means researchers rely on research-chemical sourcing channels with the corresponding quality-assurance considerations.